v3.26.1
Schedule of Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Other expense (income) $ 6,000 $ 28,656,000 $ (9,000) $ 27,500,000
Net loss 4,518,000 30,169,000 7,351,000 30,945,000
Clinical Stage Biopharmaceutical Member]        
Segment Reporting [Line Items]        
Research and development 1,055,000 363,000 1,468,000 1,462,000
Salaries 410,000 351,000 771,000 632,000
Insurance 43,000 61,000 83,000 121,000
Stock-based compensation 46,000 4,000 92,000 7,000
Operating expenses 2,958,000 734,000 4,946,000 1,223,000
Loss on initial recognition of Greenshoe Rights liability 28,736,000 28,736,000
Other expense (income) 6,000 (80,000) (9,000) (1,236,000)
Net loss $ 4,518,000 $ 30,169,000 $ 7,351,000 $ 30,945,000